SCHEMBL31064334

SCHEMBL31064334

O=C1COC2(CC2)c2cc(Br)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.39
S100A4 P26447 1/20 0.37
METAP1 P53582 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
MALT1 Q9UDY8 1/20 0.35
CMA1 P23946 1/20 0.34
AHR P35869 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
AKR1A1 P14550 1/20 0.33
AKR1B1 P15121 1/20 0.33
PTPRC P08575 1/20 0.33
PKM P14618 1/20 0.33
PBRM1 Q86U86 1/20 0.33
PARP10 Q53GL7 2/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17808127 0.80 TDP2 (0.39) TDP2S100A4METAP1CA1CA2
SCHEMBL31064426 0.80 METAP1 (0.40) TDP2METAP1
SCHEMBL31040700 0.80 TDP2 (0.39) TDP2S100A4METAP1CA1CA2
SCHEMBL31515349 0.77 KDM1A (0.40) TDP2CMA1AHROPRD1
SCHEMBL31064284 0.76 TDP2 (0.43) TDP2PARP10PARP1NPY5R
SCHEMBL31064257 0.76 AKR1A1 (0.40) AKR1A1AKR1B1
SCHEMBL31430262 0.72 SLC6A4 (0.40) TDP2METAP1CMA1AHROPRD1
SCHEMBL12077300 0.70 TDP2 (0.42) TDP2S100A4METAP1CA1CA2
SCHEMBL30954699 0.70 KDM1A (0.38) CMA1AHROPRD1
SCHEMBL30643108 0.70 TDP2 (0.42) TDP2S100A4METAP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 US disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 PRMT5, PRMT6, PRMT1 TDP2 412/4885S100A4 3639/4885METAP1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.